Advertisement
Lexicon will also present a separate poster titled, "Open accessmass-directed purification: Adaptation to diverse loading scales and compoundpolarities," at the same conference on August 19, 2007. The paper number is174 and will be included in the Division of Medicinal Chemistry poster sessionwhich begins at 7:00 p.m. Eastern Time.
Advertisement
About Lexicon
Lexicon is a biopharmaceutical company focused on the discovery anddevelopment of breakthrough treatments for human disease. Lexicon currentlyhas development programs underway for such areas of major unmet medical needas irritable bowel syndrome and cognitive disorders. The company has used itsproprietary gene knockout technology to discover more than 100 promising drugtargets and create an extensive pipeline of clinical and preclinical programsin the therapeutic areas of diabetes and obesity, cardiovascular disease,psychiatric and neurological disorders, cancer, immune system disorders andophthalmic disease. To advance the development and commercialization of itsprograms, Lexicon is working both independently and through collaboratorsincluding Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. Foradditional information about Lexicon and its programs, please visithttp://www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements," includingstatements relating to Lexicon's clinical development of LX1031 and thepotential therapeutic and commercial potential of LX1031. This press releasealso contains forward-looking statements relating to Lexicon's growth andfuture operating results, discovery and development of products, strategicalliances and intellectual property, as well as other matters that are nothistorical facts or information. All forward-looking statements are based onmanagement's current assumptions and expectations and involve risks,uncertainties and other important factors, specifically including thoserelating to Lexicon's ability to successfully conduct clinical development ofLX1031 and preclinical and clinical development of its other potential drugcandidates, advance additional candidates into preclinical and clinicaldevelopment, obtain necessary regulatory approvals, achieve its operationalobjectives, obtain patent protection for its discoveries and establishstrategic alliances, as well as additional factors relating to manufacturing,intellectual property rights, and the therapeutic or commercial value of itsdrug candidates, that may cause Lexicon's actual results to be materiallydifferent from any future results expressed or implied by such forward-lookingstatements. Information identifying such important factors is contained under"Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon'sannual report on Form 10-K for the year ended December 31, 2006, as filed withthe Securities and Exchange Commission. Lexicon undertakes no obligation toupdate or revise any such forward-looking statements, whether as a result ofnew information, future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.
